Afatinib vs Durvalumab

## Afatinib vs Durvalumab: Overview

This comparison examines the pharmacological differences between **Afatinib** and **Durvalumab**.

## Mechanism of Action

**Afatinib**: Irreversible covalent inhibitor of ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases.

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Afatinib — 37 hours; Durvalumab — 17 days.

## Chemical Properties

**Molecular Formula**: Afatinib — C24H25ClFN5O3; Durvalumab — N/A.

**Molecular Weight**: Afatinib — 485.9400 g/mol; Durvalumab — N/A.

**Type**: Afatinib — Small molecule; Durvalumab — Antibody.